Abnormal dopaminergic neurotransmission in the hippocampus may be involved in certain aspects of cognitive dysfunction. In the hippocampus, there is little, if any, expression of dopamine transporters (DAT), indicating that the mechanism for dopamine clearance differs from that in the striatum. Here, by means of in-vivo microdialysis in freely moving rats, we tested the hypothesis that the norepinephrine transporter (NET) is involved in dopamine clearance in the hippocampus. We found that systemic administration of the selective NET inhibitor reboxetine (3 mg/kg) and the psychostimulants amphetamine (0.5 mg/kg) and cocaine (10 mg/kg) increased hippocampal dopamine efflux. Local administration of reboxetine (300 mM) produced a large increase in hippocampal dopamine levels that could not be further enhanced by the addition of the NET/DAT inhibitor nomifensine (100 mM). Administration of the specific DAT inhibitor GBR12909 at a concentration (1 mM) that robustly increased dopamine in the nucleus accumbens had a comparably smaller effect in the hippocampus. In line with a minor role of DAT in the hippocampus, we detected very little DAT in this area using ligand binding with radiolabelled RTI-55. Moreover, in contrast to raclopride (100 mM), a dopamine D 2 -autoreceptor antagonist, local administration of the a 2 -adrenoceptor antagonist idazoxan (100 mM) increased hippocampal dopamine. Taken together, our data demonstrate an interaction between dopamine and norepinephrine systems in the hippocampus. It is proposed that this interaction originates from a shared uptake mechanism at the NET level.
Introduction
Accumulating evidence indicates that dopamine has an important role in hippocampus-dependent learning and memory (for review see Lisman & Otmakhova, 2001) . Indeed, the hippocampus receives dopamine projections from the ventral tegmental area (VTA) and the substantia nigra pars compacta (SNc) (Bischoff et al. 1979 ; Gasbarri et al. 1994 ; Verney et al. 1985) , and specific lesion of these projections impairs spatial learning in rats (Gasbarri et al. 1996) . Dopamine receptors of D 1 -type (D 1 and D 5 ) as well as D 2 -type (D 2 , D 3 and D 4 ) have been found in the hippocampus (Goldsmith & Joyce, 1994 ; Huang et al. 1992 ) and dopamine modulates hippocampal synaptic plasticity (Frey et al. 1990 ; Li et al. 2003 ; Otmakhova & Lisman, 1996) . In fMRI studies on humans, an association has been found between memory formation and the coactivation of midbrain dopamine areas and the hippocampus (Adcock et al. 2006 ; Wittmann et al. 2005 Wittmann et al. , 2007 .
Despite the important role dopamine appears to play in the hippocampus and despite its potential clinical importance, the mechanisms regulating dopamine synthesis, release and clearance in the hippocampus have remained largely unexplored. A marked difference between striatal regions and the hippocampus is that there is little, if any, dopamine transporter (DAT) protein in the hippocampus (Kwon et al. 2008 ; Mennicken et al. 1992) . Thus, the mechanism for dopamine clearance must differ between these two areas. Importantly, the condition in the hippocampus may resemble the prefrontal cortex where uptake of extracellular dopamine is mainly controlled by the more densely expressed norepinephrine transporter (NET) (Carboni et al. 1990 ; Moró n et al. 2002 ; Pozzi et al. 1994 ; Yamamoto & Novotney, 1998) . Psychostimulant drugs that target monoamine transporters, such as amphetamine and cocaine, have been shown to exert dopamine receptor-dependent effects in the hippocampus (Imperato et al. 1993) . However, based on the analogy with the prefrontal cortex, the means by which these drugs promote dopamine efflux in the hippocampus may differ from, for example, the nucleus accumbens (NAc). Indeed, the effect of cocaine on dopamine efflux in prefrontal cortex strongly relies on the inhibitory action of cocaine on NET (Moró n et al. 2002) . Moreover, desipramine, a tricyclic antidepressant drug with high selectivity for NET (Iversen, 2006) , has the ability to prolong the effect of exogenously applied dopamine to the hippocampus (Guiard et al. 2008) . A better understanding of norepinephrinedopamine interactions in the hippocampus has significance for the treatment of cognitive symptoms in psychiatric diseases such as depression, given the role of dopamine on memory, and the fact that several clinically approved antidepressant drugs act on the NET.
Based on anatomical and functional similarities with the prefrontal cortex we hypothesized that the NET is involved in clearance of extracellular dopamine in the hippocampus. To test this hypothesis, we used a pharmacological approach, measuring dopamine in the hippocampus by means of in-vivo microdialysis. We first established effects of systemically administered psychostimulant drugs, which target both transporters, and then tested the effects of the systemically administered norepinephrine reuptake inhibitor reboxetine. The interplay between dopamine and norepinephrine in the hippocampus was analysed by local application of re-uptake inhibitors of dopamine or norepinephrine as well as autoreceptor antagonists.
Materials and methods

Surgery and microdialysis
Male Wistar rats (Scanbur, Sweden) weighing about 300 g were housed under standard laboratory conditions on a 12-h normal light/dark cycle (lights on at 07 : 00 hours). Food and tap water were available ad libitum. All experiments were approved by the local ethical review committee (Stockholms Norra Djurfö rsö ksetiska nämnd). Rats were anaesthetized with a cocktail containing fentanyl citrate (0.39 mg/kg) and fluanisone (12.5 mg/kg, Hypnorm 1 , JanssenCilag, UK) and midazolam (6.25 mg/kg, Dormicum 1 , Roche AB, Sweden) diluted in distilled water (1 : 1 : 2 ; 5 ml/kg i.p.) and mounted in a stereotaxic frame. Dialysis probes were implanted at the following coordinates (in mm) : AP x5.6, ML x4.8, DV x8.2 for hippocampus, and AP +1.4, ML x1.4, DV x8.2 for NAc, relative to bregma and the dural surface (Paxinos & Watson, 1998) . Dialysis occurred through a semi-permeable membrane (Filtral AN69, Hospal Industrie, France) with an active surface length of 4 mm in hippocampus and 2.25 mm in NAc. Dialysis experiments were conducted approximately 48 h after surgery in freely moving rats. The dialysis probe was perfused with a physiological perfusion solution (in mM : 2.2 CaCl 2 , 147 NaCl, 3.0 KCl, 1.0 Na 2 HPO 4 , 0.2 NaH 2 PO 4 ) at a rate of 2.5 ml/min set by a microinfusion pump (Harvard Apparatus, USA). The Ca 2+ concentration used is recommended for areas in which the basal level of transmitter is low (Di Chiara et al. 1996) . Apparently, the concentration of Ca 2+ did not affect the basal extracellular dopamine level, since it was similar to those of reported previously (Chung et al. 2004 ; Smolders et al. 2008) . Dialysate was collected over 30-and 15-min intervals for hippocampus and NAc, respectively, and automatically injected into a high-performance liquid chromatography (HPLC) system. Online quantification of dopamine was accomplished by electrochemical detection (ESA, USA). The location of microdialysis probes was later verified in slices of formalin-fixed tissue stained with Neutral Red.
Drugs
Cocaine HCl (Apoteksbolaget, Sweden) was dissolved in saline (0.9 % NaCl) and administered subcutaneously (s.c.), atomoxetine (Tocris, UK) was dissolved in water and injected intraperitoneally (i.p.), d-amphetamine sulphate (Sigma Aldrich, Sweden) was dissolved in saline and administered i.p., and reboxetine (Pharmacia Corp., USA) was dissolved in saline or in the perfusion solution and was injected s.c. or locally applied through the dialysis probe. Control animals were injected with saline (1 ml/kg). Nomifensine maleate (RBI, USA), GBR12909 (Tocris), idazoxan (RBI), and raclopride (AstraZeneca, Sweden) were dissolved in perfusion solution and delivered to the rat brain via the dialysis probe. The concentration of each drug was chosen on the basis of the following studies : reboxetine (according to Linnér et al. 2001) , nomifensine maleate (according to Nomikos et al. 1990) , GBR12909 (by the ability of the drug to increase extracellular dopamine in the NAc), idazoxan (according to Hertel et al. 1999) , and raclopride (according to Rahman et al. 2001) .
Autoradiography
Male Wistar rats were anaesthetized with halothane (Apoteksbolaget) and decapitated. The brains were rapidly dissected, frozen on dry ice and stored at x70 xC until processed. Coronal and horizontal cryosections (14 mm) were mounted onto microscope slides and washed in 50 mM Tris-HCl (pH 7.5) before incubation with the DAT radioligand [
125 I]RTI-55 (50 pmol, 2200 Ci/mmol, PerkinElmer, Sweden) for 1 h. Fluoxetine (10 mM, Lilly, USA) was included to block binding to the serotonin transporter. For detection of unspecific binding a single assay was performed in the presence of the DAT inhibitor nomifensine (100 mM). Sections were exposed to autoradiographic film (BioMax MR-1, PerkinElmer) together with [
14 C] microscales (Amersham, UK) for 1 d. The films were manually processed with Kodak GBX-developer and fixer (Sigma Aldrich) and digitalized with a desktop scanner (Epson 1250). Binding was quantified using Image J software (NIH Image, USA).
Data analysis
Dopamine levels were expressed and statistically analysed either as absolute levels or as percent of basal levels. Baseline was defined as the average of the two and four samples for hippocampus and NAc, respectively, representing 1 h prior to drug administration. The mean percent changes were then calculated for each sample for all rats in each group. The data, presented as area under the curve (AUC), represent the average of the samples collected during 1 h of local administration. The effects of systemically administered drugs on dopamine output were compared by calculating the change in absolute numbers, i.e. subtracting the pre-injection baseline value from the average dopamine output during 1 h following injection. Unless indicated differently in the text, data were analysed by analysis of variance (ANOVA), using R software (version 2.9.2, R Development Core Team, Austria). Statistical evaluation of the overall microdialysis data was performed with linear model ANOVA using treatment as factor, whereas after local drug administration, time was used as repeatedmeasure within-subject factor. For statistically significant F tests (p<0.05), post-hoc comparisons were performed as indicated in the text, using Dunnett's or Tukey's tests. The significance level was set to a=0.05.
Results
The retention time (7.18¡0.05 min) and the level of dopamine in dialysate were referenced to a dopamine standard analysed before the experiment. The average basal dopamine levels (¡S.E.M were 0.27¡0.04 fmol/ min (0.11¡0.2 nM ; n=50) in the hippocampus and 2.85¡0.36 fmol/min (1.14¡0.14 nM ; n=17) in the NAc. The basal levels did not differ between different treatment groups [hippocampus : F group(7,42) =1.37, p>0.05 ; NAc : F group(3,13) =1.72 p>0.05]. As shown in Fig. 1 a, administration of the Na + -channel blocker tetrodotoxin (TTX, 1 mM) through the microdialysis probe decreased the levels of dopamine in the dialysate, eventually reaching a level below detection, which confirmed that hippocampal dopamine originated from action-potential-driven release of neurotransmitter.
Effect of systemic administration of psychostimulants or reboxetine
In order to clarify the effect of different drugs on dopamine levels in the hippocampus we compared two stimulant drugs, cocaine and amphetamine, known to affect DAT as well as NET, with the antidepressant reboxetine which is a selective NET inhibitor. Systemic administration of cocaine (10 mg/kg s.c.), amphetamine (0.5 mg/kg i.p.), and reboxetine (3 mg/ kg i.p.) robustly increased dopamine levels in the hippocampus [F treatment(3,19) =15.03, p<0.001, Fig. 1 b] . The increases produced by cocaine and reboxetine were significant compared to saline (p<0.05) while the effect of amphetamine on hippocampal dopamine output was significantly higher than saline (p<0.001) as well as cocaine and reboxetine (p<0.01, Tukey's test). Although the effects were slightly different in absolute numbers the effect of reboxetine suggests that dopamine efflux produced by systemic administration of cocaine and amphetamine could at least partly be explained by their direct inhibition of the transport of dopamine via NET (Moró n et al. 2002 ; Wall et al. 1995) . We also tested the effect on hippocampal dopamine efflux of another specific NET inhibitor, atomoxetine (3 mg/kg i.p.), which has recently been shown not to affect the dopamine levels in rat hippocampus (Montezinho et al. 2010) . In contrast to this previous report, but in analogy to the effect of reboxetine, we found a time-dependent increase in dopamine output following systemic administration. The average increase during 1 h post-injection was 0.92¡0.34 fmol/ min (n=3, data not shown), and there was a significant timertreatment interaction (F 3,18 =4.51, p<0.01 ; twoway ANOVA with repeated measures). 
Effect of NET and DAT inhibition
To avoid potential systemic and indirect effects and to further understand the local regulation of dopamine clearance in the hippocampus, we also administered the substances locally through the microdialysis probe. The specific NET inhibitor reboxetine (300 mM) administered locally in the hippocampus via reversed dialysis, produced a significant (p<0.001) increase in dopamine in the dialysate (Fig. 2 a) . The enhanced dopamine efflux was observed within the first 30 min and lasted throughout 1 h of reboxetine administration. The addition of the NET/DAT inhibitor nomifensine (100 mM) did not result in a further increase in dopamine (p>0.05). In contrast, in the NAc, the local inhibition of NET with reboxetine did not produce a significant (p>0.05) increase in dopamine in the dialysate, whereas the combined inhibition of NET and DAT with reboxetine and nomifensine did (Fig. 2 b) . The increase in dopamine levels was significant (p<0.001) in the first sample (15 min) following addition of nomifensine to the perfusion solution, and remained elevated throughout the 1 h of drug administration (p<0.001). The average increase in dopamine efflux during uptake inhibition (1 h) in the hippocampus and NAc is summarized in Fig. 2 c to illustrate that the pattern of effects were to a large extent opposite in the two brain regions.
To specifically examine the role of DAT, the effect of the selective DAT inhibitor GBR12909 on hippocampal dopamine levels was investigated. For comparison, we first determined a concentration of GBR12909 that had the ability to increase dopamine efflux in the NAc. As shown in Fig. 3 a, perfusion of 1 mM GBR12909, but not 100 or 300 mM, for 1 h caused a significant (p<0.05) increase in accumbal dopamine. When applied to the hippocampus for 1 h, GBR12909 (1 mM) did cause a small but significant (p<0.05) increase in hippocampal dopamine. This effect was negligible compared to the effect produced in the NAc, and most importantly, the increase in hippocampal dopamine levels was much smaller than that observed following administration of reboxetine (cf. Fig. 2 c) .
Expression of DAT was evaluated with autoradiography using the DAT radioligand [
125 I]RTI-55 (Fig. 3 b, c) . We observed a small, but significant (p<0.001, t test) specific binding in the hippocampus compared to non-specific binding measured in the presence of the blocker nomifensine. However, DAT binding in the hippocampus was only 41 % of the binding observed in the cingulate cortex (Cg in Fig.  3 c) , which has been reported to express low DAT levels compared to the striatum (Sesack et al. 1998) . Altogether, these experiments highlight the low expression of DAT specifically in the hippocampus. Comparison with histological examination of the placement of the dialysis probe illustrated, that the region in which microdialysis experiments were performed overlapped with low [
125 I]RTI-55 binding sites (Fig. 3 d) . 
Effect of inhibiton of a 2 -adrenoceptors and dopamine D 2 receptors
Based on the hypothesis that NET provides a major clearance mechanism for dopamine in the hippocampus, enhanced levels of norepinephrine would compete with dopamine uptake via the NET and increase hippocampal dopamine. To increase norepinephrine release, the a 2 -adrenoceptor was inhibited by the selective antagonist idazoxan (100 mM), administered directly to the hippocampus. Idazoxan significantly (p<0.001) enhanced dopamine output (Fig. 4 a) . 
Reboxetine Reboxetine+nomifensine
Reboxetine Nomifensine *** *** *** *** *** *** *** *** *** *** *** *** *** *** Fig. 2 . Effects of local administration of reboxetine (300 mM ; black bar), a specific NET inhibitor, followed by nomifensine (100 mM ; grey bar), a NET/DAT inhibitor, on dopamine levels in (a) the hippocampus (Hip) [F time(6,18) =12.60, p<0.001] and (b) the nucleus accumbens (NAc) [F time(12,48) =55.77, p<0.001]. Data are expressed as mean¡S.E.M. *** p<0.001 vs. the last baseline sample (t=0), one-way ANOVA with repeated measures followed by Dunnett's test (n=4-5 rats). In panel (c) the data of (a, b) are summarized as the area under the curve (AUC) during the 1-h perfusion of reboxetine (black bars) and the 1-h perfusion of reboxetine+nomifensine (grey bars), respectively. The dashed line indicates baseline. The levels remained elevated (p<0.01) for 30 min and returned to baseline values 120 min after idazoxan removal.
Inhibition of dopamine D 2 autoreceptors with local administration of the selective D 2 /D 3 receptor antagonist raclopride resulted in small effects on hippocampal dopamine (Fig. 4 b) . Although ANOVA indicated a significant effect over time (F 3,12 =3.92, p<0.05) none of the individual samples were significantly different from the baseline (p>0.05). In contrast, infusion of raclopride (100 mM) in the NAc for 1 h resulted in enhanced dopamine levels in this area (Fig. 4 b) . The dopamine output remained elevated for 30 min after the removal of raclopride.
Discussion
Our study shows that systemic administration of the psychostimulant drugs cocaine and amphetamine as well as the selective NET inhibitor reboxetine enhances dopamine levels in the hippocampus. Local inhibition of NET with reboxetine also increases extracellular levels of dopamine in the rat hippocampus. In comparison, the effect of DAT inhibition, using GBR12909 was negligible. DAT binding in the hippocampus, as determined by autoradiography, was very low. Furthermore, we report that local inhibition of a 2 -adrenoceptors with idazoxan, but not inhibition of D 2 receptors with raclopride, increases dopamine output in the hippocampus.
The NET has high affinity for dopamine (Giros et al. 1994 ; Raiteri et al. 1977) and in the prefrontal cortex, where the expression of DAT is low, NET is the main monoamine transporter for dopamine (Moró n et al. 2002) . Consequently, inhibition of NET causes not only accumulation of norepinephrine but also an increased local dopamine efflux (Carboni et al. 1990 ; Pozzi et al. 1994 ; Yamamoto & Novotney, 1998) . Based on our data and the anatomy of norepinephrine and dopamine systems in the hippocampus we suggest a similar regulation of dopamine uptake. The ventral hippocampus of the rat is innervated by dense input from the norepinephrine neurons of the locus coeruleus and a sparse projection from a subpopulation of dopaminergic neurons of the VTA. Importantly, while hippocampal norepinephrine terminals express high levels of NET (Gehlert et al. 1995 ; Schroeter et al. 2000 ; TejaniButt, 1992) , previous studies only just detected, or failed to detect, DAT in the hippocampus (Kwon et al. 2008 ; Mennicken et al. 1992) . The idea that NET controls uptake of hippocampal dopamine is consistent with the finding that systemic administration of the NET inhibitor desipramine prolongs the effect of exogenously applied dopamine to the hippocampus (Guiard et al. 2008) . Our data is an extension of previous reports of dopamine-norepinephrine interactions in the hippocampus, since we have used local application of drugs and can thereby conclude that the effect on extracellular concentrations of dopamine in the hippocampus following inhibition of NET originates at the hippocampal level. Since NET is selectively expressed by norepinephrine neurons (Lorang et al. 1994) , it is probable that the increased extracellular dopamine following reboxetine administration represents inhibition of dopamine transport into hippocampal norepinephrine terminals.
The NET and DAT cooperate, to a certain degree, in the clearance of dopamine in the prefrontal cortex as (3, 12) =3.92, p<0.05] and the nucleus accumbens (%) [F time(6,24) =3.63, p<0.05]. Data are expressed as mean¡S.E.M. * p<0.05, ** p<0.01, *** p<0.001 and nonsignificant (n.s.) vs. the last baseline sample (t=0), one-way ANOVA with repeated measures followed by Dunnett's test (n=5-6 rats).
well as in the NAc (Moró n et al. 2002) where concomitant inhibition of NET and DAT produces a cumulative effect on extracellular dopamine (Carboni et al. 2006) . Thus, although NET appears to play a major role for dopamine clearance in the hippocampus, we asked whether it would be possible to unmask a role for DAT when NET is inhibited. The lack of further effect of nomifensine in the presence of reboxetine (Fig. 2) confirms that NET has a significant role in dopamine clearance in the hippocampus and disputes a similar influence by DAT-mediated transport. It may be argued that the lack of effect of nomifensine in the hippocampus could be due to a high, non-selective, concentration of reboxetine that would mask an additional effect of DAT inhibition. However, the comparison with the analogous experiment in the NAc provides strong support that this is not the case. While local administration of reboxetine had no effect on dopamine levels in the NAc, the addition of nomifensine potently increased accumbal dopamine levels. It could then be argued that the concentration of reboxetine in the NAc experiment was too low and that the effect of nomifensine was due to an increased level of NET blockade. Had this been the case, then nomifensine would have been expected to produce an additional increase in extracellular dopamine in the hippocampus. Thus, under the present experimental conditions, it appears that nomifensine acts preferentially as a DAT inhibitor in the presence of reboxetine. Since the addition of nomifensine did not result in a cumulative effect on the dopamine efflux produced by reboxetine in the hippocampus our data suggest that inhibiting DAT is largely ineffective in enhancing hippocampal dopamine levels.
The involvement of NET in dopamine uptake can explain the effects on hippocampal dopamine of imipramine (Smolders et al. 2008) and desipramine (Guiard et al. 2008 ). The conclusion made in this study is mainly supported by the selectivity of reboxetine for NET compared to other monoamine transporters (Iversen, 2006 ; Wong et al. 2000) . Surprisingly, a recent study found that atomoxetine, which has similar selectivity for NET as reboxetine (Bymaster et al. 2002) , did not stimulate hippocampal dopamine efflux (Montezinho et al. 2010) . In contrast, we found a robust increase following systemic administration of the equivalent dose. Although we can only speculate on the source of our conflicting results, Montezinho et al. (2010) report a substantially higher basal hippocampal dopamine concentration, which might have masked a potentiating effect of atomoxetine.
While our experiments with nomifensine indicated lack of DAT activity, we found support for a minor role of DAT using the specific DAT inhibitor GBR12909. This finding is in agreement with previous studies (Smolders et al. 2008 ; Xu et al. 1993 ) and argues for a role of DAT in hippocampal dopamine uptake. To make the comparison between the role of DAT and NET on dopamine uptake, we first determined a concentration of GBR12909 that had the ability to increase dopamine efflux in NAc (cf. Fig. 3) . While 1 mM GBR12909 may appear rather high, estimations on reversed recovery suggest that the concentration in brain will be 0.2-0.5 % of the administered concentration (Marshall et al. 1997 ; Toth et al. 1993) . Directly applied to our experiment such recovery would yield low micromolar concentrations of GBR12909 which is consistent with the concentrations needed to inhibit 80 % of dopamine reuptake in accumbal synaptosomes (Moró n et al. 2002) . This DAT-specific concentration increased dopamine levels in the hippocampus to a much smaller extent than did reboxetine (cf. Figs 2 and 3). Thus, our results demonstrate a small but significant effect of DAT on dopamine in the ventral hippocampus. Additional support for a minor role of DAT for dopamine reuptake in hippocampus is derived from our radioligand binding studies with [
125 I]RTI-55 that showed significant but markedly low expression of DAT in the hippocampus.
According to the hypothesis that dopamine in the hippocampus is predominantly cleared by NET, increased levels of norepinephrine in the hippocampus should be accompanied with increased dopamine levels, solely due to competition between norepinephrine and dopamine of the NET transport mechanism. The selective a 2 -adrenoreceptor antagonist idazoxan has been shown to increase norepinephrine in the hippocampus (Carter, 1997) and, indeed, local administration of idazoxan increased hippocampal dopamine. Theoretically, idazoxan could increase hippocampal dopamine output by direct effects on dopamine release through removal of an inhibitory tone exerted by norepinephrine on a 2 -adrenoceptors located on either norepinephrine or dopaminergic terminals. However, the increased dopamine output that follows inhibition of NET argues against this explanation since dopamine efflux would then decrease as a consequence of enhanced a 2 -adrenoceptor stimulation by norepinephrine. An alternative explanation that appears more congruent with the present data is the possibility that norepinephrine and dopamine are co-released from the same terminals (Devoto et al. 2001 (Devoto et al. , 2008 and that a 2 -adrenoreceptors negatively influence this process. Yet, inhibition of dopamine b-hydroxylase, the enzyme that converts dopamine to norepinephrine, does not increase hippocampal dopamine levels while it effectively reduces norepinephrine content (Xu et al. 1993) suggesting that the dopamine detected in the hippocampus may originate from a source separate from that of norepinephrine.
Dopamine release in the NAc and the striatum is controlled by the tonic activity of dopamine D 2 autoreceptors (see Schmitz et al. 2003) . The weak effect of local administration of raclopride in the hippocampus indicated that dopamine release from terminals in the hippocampus is not tonically inhibited by D 2 receptors, at least not to the same degree as in the NAc. It is possible, however, that the effect of D 2 receptor blockade in the hippocampus is masked because of a rapid dopamine uptake via NET. Indeed, not even in the NAc where D 2 receptors are known to play a critical role on dopamine neurotransmission, did the maximal increase reach the levels observed following uptake inhibition (cf. Figs 2 and 3) . These results are consistent with the more significant role of uptake than release control in setting the basal extracellular dopamine levels (Venton et al. 2003) . It will be necessary to address D 2 receptor function in the hippocampus in more detail in future studies.
In summary, our study suggests a pronounced interplay between dopamine and norepinephrine systems in the control of extracellular dopamine levels in the hippocampus, originating from a shared uptake mechanism through the NET. The present study may have important clinical implications for the treatment of cognitive impairments in neuropsychiatric diseases, given the proposed role of dopamine in memory formation in the hippocampus. Inhibition of a 2 -adrenoceptors or NET is the mechanism of action of several currently used antidepressant drugs, including reboxetine, and these mechanisms may also represent promising targets for future development of antipsychotic drugs.
